Moreover, a rebound activation of MEK/ERK was not persistent upon treatment with LY3009120, thereby differentiating this compound from BRAF selective inhibitors that have been shown to be ineffective in BRAFmut CRC due to EGFR-mediated activation of MEK/ERK through activation of the RAS-CRAF axis [26]. This evidence concerns the gene EGFR and colorectal carcinoma.